Thomas Böldicke

Dr. Thomas Böldicke received his PhD 1982 at the Max-Planck-Institut of Molecular Genetics, Berlin. He started his carrier as post doc at the German Research Centre for Biotechnology (GBF, Braunschweig, Germany) in the Department of Genetics and Cell Biology by John Collins. Now he is senior scientist at the Helmholtz Centre for Infection Research (HZI, former GBF) and project leader intrabodies. He developed recombinant antibodies against tumor antigens, particularly against tumour angiogenesis, rhabdyomyosarcoma and recently against TLR2 and TLR9 in pancreatic cancer. He edited two books: "Protein Targeting Compounds" with Springer (2016) and "Antibody Engineering" with IntechOpen (2017). He has published dozends papers on many international journals. Over 10 years he gave lectures at the Technical University in Braunschweig about immunology, cancer development and immunotherapies. He is in the editorial board of the journal Antibodies as academic editor, Frontiers in Immunology and Frontiers in Oncology.